Study details
Enrolling now
A Study of NT-175 in Adults With Advanced Solid Tumors
AstraZeneca
NCT IDNCT05877599ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
162
Study length
about 16 years
Ages
18+
Locations
18 sites in AZ, CA, FL +9
About this study
This trial is testing a new treatment called NT-175, which are engineered T cells. The goal is to see if this treatment can help people with advanced solid tumors that have specific genetic changes.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Autologous, engineered T Cells targeting TP53 R175H
PhasePhase 1
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Oncology